Cargando…

Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry

BACKGROUND: Patients aged 65 years and older represent the majority of patients with metastatic colorectal cancer (mCRC). However, this patient population is often underrepresented in clinical trials and probably undertreated in the clinical practice. METHODS: We have analysed the outcomes of 3,187...

Descripción completa

Detalles Bibliográficos
Autores principales: Slavicek, Lubomir, Pavlik, Tomas, Tomasek, Jiri, Bortlicek, Zbynek, Buchler, Tomas, Melichar, Bohuslav, Vyzula, Rostislav, Prausova, Jana, Finek, Jindrich, Majek, Ondrej, Dusek, Ladislav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987650/
https://www.ncbi.nlm.nih.gov/pubmed/24666582
http://dx.doi.org/10.1186/1471-230X-14-53
_version_ 1782479694322466816
author Slavicek, Lubomir
Pavlik, Tomas
Tomasek, Jiri
Bortlicek, Zbynek
Buchler, Tomas
Melichar, Bohuslav
Vyzula, Rostislav
Prausova, Jana
Finek, Jindrich
Majek, Ondrej
Dusek, Ladislav
author_facet Slavicek, Lubomir
Pavlik, Tomas
Tomasek, Jiri
Bortlicek, Zbynek
Buchler, Tomas
Melichar, Bohuslav
Vyzula, Rostislav
Prausova, Jana
Finek, Jindrich
Majek, Ondrej
Dusek, Ladislav
author_sort Slavicek, Lubomir
collection PubMed
description BACKGROUND: Patients aged 65 years and older represent the majority of patients with metastatic colorectal cancer (mCRC). However, this patient population is often underrepresented in clinical trials and probably undertreated in the clinical practice. METHODS: We have analysed the outcomes of 3,187 mCRC patients treated with first-line bevacizumab based on data from the Czech national registry of mCRC patients aiming to compare the treatment efficacy and safety according to the age categories. RESULTS: In total, 2,126 (66.7%), 932 (29.2%), and 129 (4.0%) patients were aged <65 years, 65 to 75 years, and 75+ years, respectively. Median progression-free survival (PFS) was 11.4, 11.3, and 11.8 months for patients aged <65 years, 65 to 75 years, and 75+ years, respectively (p = 0.94). Median overall survival (OS) was 26.9, 27.5, and 25.1 months for patients aged <65 years, 65 to 75 years, and 75+ years, respectively (p = 0.73). Using multivariable Cox model for both PFS and OS, the patient age was not significantly associated with either PFS or OS. No increase in bevacizumab-related toxicity was observed among the elderly mCRC patients with the exception of hypertension, which was observed in 71 (3.3%), 34 (3.6%), and 10 (7.8%) patients aged <65 years, 65 to 75 years, and 75+ years, respectively. CONCLUSIONS: The results of the present study suggest similar outcome in terms of OS and PFS with bevacizumab-containing therapy in elderly mCRC patients fit for chemotherapy combined with targeted therapy compared to younger patients. Thus, chronological age should not be considered to represent a limitation in prescribing bevacizumab-containing therapy in mCRC patients.
format Online
Article
Text
id pubmed-3987650
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39876502014-04-16 Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry Slavicek, Lubomir Pavlik, Tomas Tomasek, Jiri Bortlicek, Zbynek Buchler, Tomas Melichar, Bohuslav Vyzula, Rostislav Prausova, Jana Finek, Jindrich Majek, Ondrej Dusek, Ladislav BMC Gastroenterol Research Article BACKGROUND: Patients aged 65 years and older represent the majority of patients with metastatic colorectal cancer (mCRC). However, this patient population is often underrepresented in clinical trials and probably undertreated in the clinical practice. METHODS: We have analysed the outcomes of 3,187 mCRC patients treated with first-line bevacizumab based on data from the Czech national registry of mCRC patients aiming to compare the treatment efficacy and safety according to the age categories. RESULTS: In total, 2,126 (66.7%), 932 (29.2%), and 129 (4.0%) patients were aged <65 years, 65 to 75 years, and 75+ years, respectively. Median progression-free survival (PFS) was 11.4, 11.3, and 11.8 months for patients aged <65 years, 65 to 75 years, and 75+ years, respectively (p = 0.94). Median overall survival (OS) was 26.9, 27.5, and 25.1 months for patients aged <65 years, 65 to 75 years, and 75+ years, respectively (p = 0.73). Using multivariable Cox model for both PFS and OS, the patient age was not significantly associated with either PFS or OS. No increase in bevacizumab-related toxicity was observed among the elderly mCRC patients with the exception of hypertension, which was observed in 71 (3.3%), 34 (3.6%), and 10 (7.8%) patients aged <65 years, 65 to 75 years, and 75+ years, respectively. CONCLUSIONS: The results of the present study suggest similar outcome in terms of OS and PFS with bevacizumab-containing therapy in elderly mCRC patients fit for chemotherapy combined with targeted therapy compared to younger patients. Thus, chronological age should not be considered to represent a limitation in prescribing bevacizumab-containing therapy in mCRC patients. BioMed Central 2014-03-25 /pmc/articles/PMC3987650/ /pubmed/24666582 http://dx.doi.org/10.1186/1471-230X-14-53 Text en Copyright © 2014 Slavicek et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Slavicek, Lubomir
Pavlik, Tomas
Tomasek, Jiri
Bortlicek, Zbynek
Buchler, Tomas
Melichar, Bohuslav
Vyzula, Rostislav
Prausova, Jana
Finek, Jindrich
Majek, Ondrej
Dusek, Ladislav
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
title Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
title_full Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
title_fullStr Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
title_full_unstemmed Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
title_short Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
title_sort efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the czech population-based registry
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987650/
https://www.ncbi.nlm.nih.gov/pubmed/24666582
http://dx.doi.org/10.1186/1471-230X-14-53
work_keys_str_mv AT slaviceklubomir efficacyandsafetyofbevacizumabinelderlypatientswithmetastaticcolorectalcancerresultsfromtheczechpopulationbasedregistry
AT pavliktomas efficacyandsafetyofbevacizumabinelderlypatientswithmetastaticcolorectalcancerresultsfromtheczechpopulationbasedregistry
AT tomasekjiri efficacyandsafetyofbevacizumabinelderlypatientswithmetastaticcolorectalcancerresultsfromtheczechpopulationbasedregistry
AT bortlicekzbynek efficacyandsafetyofbevacizumabinelderlypatientswithmetastaticcolorectalcancerresultsfromtheczechpopulationbasedregistry
AT buchlertomas efficacyandsafetyofbevacizumabinelderlypatientswithmetastaticcolorectalcancerresultsfromtheczechpopulationbasedregistry
AT melicharbohuslav efficacyandsafetyofbevacizumabinelderlypatientswithmetastaticcolorectalcancerresultsfromtheczechpopulationbasedregistry
AT vyzularostislav efficacyandsafetyofbevacizumabinelderlypatientswithmetastaticcolorectalcancerresultsfromtheczechpopulationbasedregistry
AT prausovajana efficacyandsafetyofbevacizumabinelderlypatientswithmetastaticcolorectalcancerresultsfromtheczechpopulationbasedregistry
AT finekjindrich efficacyandsafetyofbevacizumabinelderlypatientswithmetastaticcolorectalcancerresultsfromtheczechpopulationbasedregistry
AT majekondrej efficacyandsafetyofbevacizumabinelderlypatientswithmetastaticcolorectalcancerresultsfromtheczechpopulationbasedregistry
AT dusekladislav efficacyandsafetyofbevacizumabinelderlypatientswithmetastaticcolorectalcancerresultsfromtheczechpopulationbasedregistry